A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo (original) (raw)
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
Fengtian Xue
The Journal of clinical investigation, 2016
View PDFchevron_right
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Tilman Voss
Cell Reports, 2017
View PDFchevron_right
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6
Philip Rawlins
ACS Chemical Biology, 2018
View PDFchevron_right
A Peptomimetic Inhibitor of BCL6 With Potent Anti-Lymphoma Effects in vitro and in vivo
Leandro Cerchietti
2008
View PDFchevron_right
Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening
Istvan Enyedy
Journal of Medicinal Chemistry, 2001
View PDFchevron_right
Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1
Anton-Scott Goustin
Clinical cancer research : an official journal of the American Association for Cancer Research, 2007
View PDFchevron_right
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
Wayne Fairbrother
ACS Medicinal Chemistry Letters, 2014
View PDFchevron_right
Structure-guided design of a selective BCL-XL inhibitor
Ian Street
Nature Chemical Biology, 2013
View PDFchevron_right
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins
Chao-yie Yang
Journal of medicinal …, 2006
View PDFchevron_right
Computational designing of novel inhibitors to Bcl-B, an anti-apoptotic protein, using fragment-based drug designing approach
biswajit gorai
View PDFchevron_right
BCL-2 as Target for Molecular Docking of Some Neoplastic Drugs
Kaiser Jamil
2012
View PDFchevron_right
Identification of unique binding site and molecular docking studies for structurally diverse Bcl-xL inhibitors
SYED SHAHMIR AZAM
Medicinal Chemistry Research, 2014
View PDFchevron_right
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors
Philip Rawlins
Journal of medicinal chemistry, 2017
View PDFchevron_right
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
Mark Heaney
Blood, 2008
View PDFchevron_right
Design, Synthesis, and Computational Studies of Inhibitors of Bcl-XL
Hussain Raza
Journal of the American Chemical Society, 2006
View PDFchevron_right
A Potent and Highly Efficacious Bcl-2/Bcl-xL Inhibitor
Chao-yie Yang
Journal of Medicinal Chemistry, 2013
View PDFchevron_right
Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain
Mark Glenn
The FEBS Journal, 2016
View PDFchevron_right
Virtual Screening and Elucidation of Putative Binding Mode for Small Molecule Antagonist of BCL2 BH4 Domain
Temidayo Adigun
2020
View PDFchevron_right
S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
Erick Morris
Oncotarget, 2018
View PDFchevron_right
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
Wayne Fairbrother
ACS medicinal chemistry letters, 2014
View PDFchevron_right
A Novel Approach for Characterizing Protein Ligand Complexes: Molecular Basis for Specificity of Small-Molecule Bcl-2 Inhibitors
Amr Fahmy
Journal of the American Chemical Society, 2002
View PDFchevron_right
Small-Molecule Inhibitors of Bcl-2 Family Proteins Are Able to Induce Tumor Regression in a Mouse Model of Pre-B-Cell Acute Lymphocytic Lymphoma
Ramzi Mohammad, Anton-Scott Goustin
DNA and Cell Biology, 2008
View PDFchevron_right
Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737
Nathalie Bonnefoy
Journal of Biomolecular Screening, 2014
View PDFchevron_right
Group-Based Quantitative Structural Activity Relationship Analysis of B-Cell Lymphoma Extra Large (BCL-XL) Inhibitors
Nadia Hanis
View PDFchevron_right